Thyroid disease

Papillary Thyroid Cancer - 2019 Pipeline Insight Study - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2019
Health, Oncology, Pharmaceutical, Glands, Human anatomy, Organ systems, RTT, Thyroid disease, Thyroid cancer, Thyroid, Papillary thyroid cancer, Cancer, Drug pipeline

The "Papillary Thyroid Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Papillary Thyroid Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Papillary Thyroid Cancer development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for Papillary Thyroid Cancer
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Papillary Thyroid Cancer
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer

Retrieved on: 
Monday, March 25, 2019
Surgery, Technology, Data management, Health, Biotechnology, Clinical trials, Genetics, Medical devices, Oncology, Pharmaceutical, Research, Science, Thyroid disease, RTT, Glands, Human anatomy, Organ systems, Endocrine system, Thyroid cancer, Thyroid, Cancer

(Nasdaq: VCYT) announced today that new data from the Afirma Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes.

Key Points: 
  • (Nasdaq: VCYT) announced today that new data from the Afirma Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes.
  • The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid nodule diagnosis.
  • The Afirma Xpression Atlas includes 761 DNA variants and 130 RNA fusion partners in over 500 genes that are associated with thyroid cancer.
  • Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005582/en/

Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019

Retrieved on: 
Monday, March 18, 2019
Surgery, Health, Biotechnology, Clinical trials, Genetics, Medical devices, Oncology, Thyroid disease, Glands, Human anatomy, Anatomy, Thyroid, Endocrine system

S.G. Waguespack, M.D., University of Texas MD Anderson Cancer Center, Houston, Texas

Key Points: 
  • S.G. Waguespack, M.D., University of Texas MD Anderson Cancer Center, Houston, Texas
    The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid nodule diagnosis.
  • The Afirma Xpression Atlas includes 761 DNA variants and 130 RNA fusion partners in over 500 genes that are associated with thyroid cancer.
  • Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions.
  • Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190318005244/en/

The Autoimmune Disease Diagnostics Market to Hit $16 Billion by 2025: Global Market Insights, Inc.

Retrieved on: 
Tuesday, March 5, 2019
Medical specialties, Medicine, Health, Thyroid disease, Aging-associated diseases, RTT, Autoimmune diseases, Endocrine diseases, Autoimmunity, Siemens Healthineers, Abbott Laboratories, Hashimoto's thyroiditis

Global Autoimmune Disease Diagnostics Market will exceed USD 16.0 billion by 2025; according to a new research report by Global Market Insights, Inc.

Key Points: 
  • Global Autoimmune Disease Diagnostics Market will exceed USD 16.0 billion by 2025; according to a new research report by Global Market Insights, Inc.
  • Rising prevalence of autoimmune disorders such as rheumatoid arthritis, Hashimoto's thyroiditis, type 1 diabetes and Grave's disease will drive the global autoimmune disease diagnostics market.
  • UK autoimmune disease diagnostics market should witness considerable growth over the coming years.
  • Some of the key industry players operating in global autoimmune disease diagnostics market are Siemens Healthcare, Roche Diagnostics, Abbott Laboratories, BioMerieux, EUROIMMUN and Quest Diagnostics.

Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints

Retrieved on: 
Thursday, February 28, 2019
Health, Biotechnology, Clinical trials, Optical, Pharmaceutical, FDA, General Health, Thyroid disease, Glands, Organ systems, Thyroid, Human anatomy, Autoimmune diseases, Graves' ophthalmopathy, Teprotumumab, Horizon Pharma

Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).

Key Points: 
  • Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).
  • All secondary endpoints were also met and the safety profile was consistent with the Phase 2 study of teprotumumab in TED.
  • The dramatic results of the teprotumumab Phase 3 confirmatory trial, in addition to positive Phase 2 data, form a highly convincing body of clinical evidence supporting teprotumumab for the treatment of active thyroid eye disease, said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.
  • If approved, teprotumumab would give physicians the first medicine shown to reduce proptosis during active thyroid eye disease, in addition to treating other painful symptoms.

Global Anaplastic Thyroid Cancer Clinical Trials Review, H2 2018 by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Monday, February 25, 2019
Health, Clinical trials, Oncology, Health, Glands, Human anatomy, Thyroid disease, Anaplastic thyroid cancer, Thyroid cancer, Thyroid, Clinical trial, Anaplastic lymphoma kinase

The "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Anaplastic Thyroid Cancer clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Anaplastic Thyroid Cancer.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Advanced Bioidentical Hormone Therapy Welcomes New Team Member

Retrieved on: 
Monday, January 21, 2019
Medicine, Health, Menopause, Thyroid disease, Bioidentical hormone replacement therapy, Hormone therapy, Therapy, Kent Holtorf

HOUSTON, Jan. 21, 2019 /PRNewswire-PRWeb/ -- Advanced Bioidentical Hormone Therapy has always been committed to bringing the best team members on board to provide top-notch patient care.

Key Points: 
  • HOUSTON, Jan. 21, 2019 /PRNewswire-PRWeb/ -- Advanced Bioidentical Hormone Therapy has always been committed to bringing the best team members on board to provide top-notch patient care.
  • Personal tragedy sparked her interest in bioidentical hormone therapy.
  • That's why I'm excited to join the exceptional team of providers at AB Hormone Therapy, where I can continue to offer comprehensive care to my patients."
  • AB Hormone Therapy offers bioidentical hormone treatment for men and women suffering from the symptoms of aging, including adrenal fatigue, thyroid disease, metabolic syndrome, and sexual dysfunction.

A 2015 Guideline Recommending Removal of Only Half the Thyroid Gland Grows in Use, Benefits Patients with Thyroid Cancer

Retrieved on: 
Monday, October 22, 2018
Medicine, Thyroid disease, Clinical medicine, Thyroid, Endocrine surgery, RTT, Surgical oncology, Thyroidectomy, Thyroid cancer, Papillary thyroid cancer, Computed tomography of the thyroid

* Traditionally, the vast majority of these patients undergo complete removal of the thyroid glandknown as a total thyroidectomyto treat their cancer rather than the less invasive hemithyroidectomy, which involves removal of half of the gland.

Key Points: 
  • * Traditionally, the vast majority of these patients undergo complete removal of the thyroid glandknown as a total thyroidectomyto treat their cancer rather than the less invasive hemithyroidectomy, which involves removal of half of the gland.
  • The study findings showed that, before the American Thyroid Association (ATA) adopted its new guidelines in 2015, 15.6 percent of patients with thyroid cancer underwent a hemithyroidectomy.
  • The trend could be significant for improving outcomes and reducing costs of care for people with thyroid cancer.
  • "These structures are behind both sides, or lobes, of the thyroid gland and can be injured during a thyroid procedure.

Triad Of Health Family Healing Center Reveals The Seven Pitfalls You Must Avoid To Heal Your Thyroid

Retrieved on: 
Monday, June 18, 2018
Thyroid disease, Anatomy, RTT, Medicine, Autoimmune diseases, Thyroid, Thyroiditis, Hashimoto's thyroiditis, Autoimmunity, Graves' disease

In the conventional medical model, the main therapies available for Hashimoto's Thyroiditis and Grave's Disease are prescription or other medications, surgical removal of the thyroid, and possibly radiation therapy or a combination thereof.

Key Points: 
  • In the conventional medical model, the main therapies available for Hashimoto's Thyroiditis and Grave's Disease are prescription or other medications, surgical removal of the thyroid, and possibly radiation therapy or a combination thereof.
  • The Triad Of Health System provides for an infinite number of therapies to choose from.
  • This unique system of checks and balances is light years ahead of any other therapeutic modality currently available.
  • Follow this link to register for and learn more about The Seven Pitfalls You Must Avoid To Heal Your Auto-Immune Thyroid event:
    Triad Of Health Family Healing Center is located in Northern California at 4340 Redwood Highway, Suite D318, San Rafael, CA 94903.

The global thyroid gland disorder treatment market size is expected to reach USD 2.6 billion by 2025

Retrieved on: 
Tuesday, May 22, 2018
Thyroid disease, Anatomy, Endocrine system, Thyroid, Hyperthyroidism, British Thyroid Foundation, Thyroid disease in pregnancy, Book:Thyroid

LONDON, May 22, 2018 /PRNewswire/ -- Thyroid Gland Disorder Treatment Market Analysis Report By Indication (Hypothyroidism, Hyperthyroidism), By RoA (Oral, Intravenous), By Distribution Channel, And Segment Forecasts, 2018 - 2025

Key Points: 
  • LONDON, May 22, 2018 /PRNewswire/ -- Thyroid Gland Disorder Treatment Market Analysis Report By Indication (Hypothyroidism, Hyperthyroidism), By RoA (Oral, Intravenous), By Distribution Channel, And Segment Forecasts, 2018 - 2025
    The global thyroid gland disorder treatment market size is expected to reach USD 2.6 billion by 2025, according to a new report by Grand View Research, Inc., and exhibit a 3.2% CAGR during the forecast period.
  • Increase in prevalence of thyroid diseases around the globe is expected to drive demand for anti-thyroid drugs in the coming years.
  • Growing awareness about disease management amongst healthcare professionals and patients is another factor augmenting market growth.
  • There are various private and public organizations working toward spreading awareness related to disease management, such as British Thyroid Foundation,The American Thyroid Association (ATA), and Thyroid Foundation of Canada.